The genetic alteration profiling of LCN2 showed that its amplification was one of the most important single factors for alteration in ACC, cervical adenocarcinoma, ESCC, PAAD, ovarian epithelial tumor, diffuse glioma, HNSC, HCC, BRCA, glioblastoma, renal non-clear cell carcinoma and PAAD. This evidence concerns the gene LCN2 and adrenal cortex carcinoma.